合计75亿美元!艾伯维和罗氏下注的Amylin靶点的神奇发现故事

药时代
16 Mar

hiPSCs从基础研究到医疗革新系列课第2期:从实验室到临床,hiPSC技术如何引领医疗转型 | 药时代直播间靶向蛋白降解技术:为生命科学研究与药物研发赋能 | 药时代直播间正文共:3000字8图预计阅读时间:6分钟2025年3月3日,艾伯维宣布与丹麦生物技术公司Gubra达成一项许可协议,共同开发GUB014295。这是一种潜在的长效胰淀素类似物(Amylin Analog),用于治疗肥胖症。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10